BiotechTube
Medherant

Medherant

Coventry, United Kingdom· Est.
medherant.co.uk
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.2M

Overview

Medherant is a UK-based, clinical-stage biotech focused on advancing transdermal drug delivery via its proprietary TEPI Patch® technology. Founded in 2014 with roots in University of Warwick polymer chemistry, the company is developing its own pipeline, starting with a testosterone patch for women's health, and offers a collaborative platform for partners. Having completed a positive Phase 1 trial for its lead asset, Medherant is positioned to address significant unmet needs in hormone therapy and pain management with a potentially superior patch format.

Women's HealthPain

Technology Platform

TEPI Patch®: A proprietary, solvent-free, drug-in-adhesive transdermal patch platform based on a novel pressure-sensitive adhesive (S-PURE) that allows for high drug payload, customizable release profiles, superior adhesion, and excellent skin tolerability.

Funding History

1
Total raised:$1.2M
Grant$1.2M

Opportunities

The large, underserved market for women's health therapies, particularly in menopause and HSDD, presents a direct opportunity for its lead patch.
Furthermore, the flexible TEPI Patch® platform allows for expansion into other therapeutic areas like pain management and offers a partnership-based revenue model by enabling transdermal delivery for third-party drug compounds.

Risk Factors

Key risks include clinical trial failure in later-stage studies for its lead program, the challenge of commercial adoption in a competitive market, and dependence on securing additional funding to advance development and scale operations.
The broad validation of its platform technology across diverse drug molecules also carries technical risk.

Competitive Landscape

Medherant competes in the transdermal drug delivery market against established patch manufacturers and alternative delivery forms (gels, creams, oral). For HSDD, it faces competition from compounded therapies and off-label use of male testosterone products. Its differentiation lies in its female-specific design, high-payload adhesive technology, and potential for superior convenience and dose control.

More companies in United Kingdom →